TABLE 1.
Eperezolid (PNU-100592), linezolid (PNU-100766), and vancomycin activities against selected pathogens
| Organism (no. of isolates) | Agent | MIC (μg/ml)a
|
||
|---|---|---|---|---|
| MIC range | 50% | 90% | ||
| S. aureus | ||||
| Methicillin susceptible (100) | Eperezolid | 1.0–8.0 | 2.0 | 2.0 |
| Linezolid | 1.0–8.0 | 2.0 | 4.0 | |
| Vancomycin | 0.25–1.0 | 0.5 | 1.0 | |
| Methicillin resistant (100) | Eperezolid | 1.0–8.0 | 2.0 | 4.0 |
| Linezolid | 1.0–8.0 | 2.0 | 4.0 | |
| Vancomycin | 0.25–2.0 | 1.0 | 1.0 | |
| S. epidermidis | ||||
| Methicillin-susceptible (24) | Eperezolid | 0.5–2.0 | 1.0 | 1.0 |
| Linezolid | 1.0–2.0 | 1.0 | 2.0 | |
| Vancomycin | 0.25–2.0 | 1.0 | 2.0 | |
| Methicillin-resistant (35) | Eperezolid | 0.5–2.0 | 1.0 | 1.0 |
| Linezolid | 0.5–4.0 | 1.0 | 2.0 | |
| Vancomycin | 0.5–2.0 | 1.0 | 2.0 | |
| Coagulase-negative staphylococcus (non-S. epidermidis) | ||||
| Methicillin-susceptible (25) | Eperezolid | 0.5–2.0 | 1.0 | 1.0 |
| Linezolid | 0.5–2.0 | 1.0 | 2.0 | |
| Vancomycin | 0.13–2.0 | 1.0 | 1.0 | |
| Methicillin-resistant (16) | Eperezolid | 1.0–2.0 | 1.0 | 1.0 |
| Linezolid | 1.0–2.0 | 1.0 | 2.0 | |
| Vancomycin | 0.5–2.0 | 1.0 | 2.0 | |
| E. faecalis (25)b | Eperezolid | 1.0–4.0 | 1.0 | 4.0 |
| Linezolid | 1.0–4.0 | 2.0 | 4.0 | |
| Vancomycin | 0.5–>64.0 | 1.0 | >64.0 | |
| E. faecium (25)b | Eperezolid | 0.5–4.0 | 2.0 | 2.0 |
| Linezolid | 0.5–4.0 | 2.0 | 2.0 | |
| Vancomycin | 0.5–>64.0 | >64.0 | >64.0 | |
a
50% and 90%, MICs for 50 and 90% of the isolates, respectively.
b
Includes 20 vancomycin-resistant isolates.